https://www.pharmaradar360.com/article/61ae4ac5a63adda0PharmaRadar360en2026-04-21T11:00:00.000ZThis simple house may help prevent multiple fatal diseases in African childrenhttps://www.pharmaradar360.com/article/3c5d711868c1bdf3PharmaRadar360en2026-04-21T10:52:13.000ZHow do Forecasting Approaches and Methodologies Change Through the Product Lifecycle?https://www.pharmaradar360.com/article/c99e19485d625432PharmaRadar360en2026-04-21T10:51:49.000ZLa AEMPS desmiente el “callo solar” y recuerda la importancia de una exposición solar segurahttps://www.pharmaradar360.com/article/7dac9c55aaf56eeePharmaRadar360en2026-04-21T10:45:00.000ZMerck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)https://www.pharmaradar360.com/article/bd7f2b6559c0ae17PharmaRadar360en2026-04-21T10:41:42.000ZHow to tell complex stories in an engaging wayhttps://www.pharmaradar360.com/article/d7bfc89aeb7fd6f0PharmaRadar360en2026-04-21T10:41:05.000ZBoletín del Comité de Medicamentos de Uso Humano. Marzo de 2026https://www.pharmaradar360.com/article/2225ca33e6df64c9PharmaRadar360en2026-04-21T10:39:38.000ZUniverCities 2026 Conference: Call for papers open!https://www.pharmaradar360.com/article/18bd05fedfef3138PharmaRadar360en2026-04-21T10:33:59.000ZSoleno sold at a discount to Neurocrine due to dwindling European prospectshttps://www.pharmaradar360.com/article/00a278064277f363PharmaRadar360en2026-04-21T10:32:32.000ZTenvie doses first subject in Phase I TNV108 trial for peripheral neuropathieshttps://www.pharmaradar360.com/article/b3191f76e820ea87PharmaRadar360en2026-04-21T10:30:42.000ZFlagship’s latest startup aims to solve gene therapy’s thorniest technical challengehttps://www.pharmaradar360.com/article/b5f3a67237b09ce9PharmaRadar360en2026-04-21T10:30:07.000ZDigital Health Coffee Time Briefing ☕https://www.pharmaradar360.com/article/2cea1f39fe8431c0PharmaRadar360en2026-04-21T10:05:53.000ZEli Lilly doubles down on in vivo with $7bn Kelonia buyouthttps://www.pharmaradar360.com/article/591f90bc57cafd04PharmaRadar360en2026-04-21T10:00:26.000ZPeople want reform of AI regulation in healthcare but not overhaulhttps://www.pharmaradar360.com/article/2790423ff56469c3PharmaRadar360en2026-04-21T10:00:00.000ZWhy KFF Is Launching a Podcast on the Business of Healthhttps://www.pharmaradar360.com/article/93596bbb25972a3dPharmaRadar360en2026-04-21T09:53:06.000ZData science: has AI solved drug discovery?https://www.pharmaradar360.com/article/13f28a4534941c04PharmaRadar360en2026-04-21T09:35:56.000ZPfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyhttps://www.pharmaradar360.com/article/84a58b9e804169d0PharmaRadar360en2026-04-21T09:30:24.000ZAstraZeneca’s COPD drug gains third Phase III winhttps://www.pharmaradar360.com/article/ac0c8f3eef67aaeaPharmaRadar360en2026-04-21T09:21:08.000ZΕνημέρωση για την υποβολή των αιτημάτων τιμολόγησηςhttps://www.pharmaradar360.com/article/e3306265a9397fefPharmaRadar360en2026-04-21T09:21:01.000ZStatutory guidance: MHRA feeshttps://www.pharmaradar360.com/article/52ed55dc970dd8e5PharmaRadar360en2026-04-21T08:37:21.000ZAtsena secures DMC approval for LIGHTHOUSE trialhttps://www.pharmaradar360.com/article/390177994a77ea11PharmaRadar360en2026-04-21T08:34:42.000ZAsahi Kasei acquires German company Aicurishttps://www.pharmaradar360.com/article/74e8426fb4b21933PharmaRadar360en2026-04-21T08:19:52.000ZPaul-Martini-Preis für Professor Dr. Alwin Krämerhttps://www.pharmaradar360.com/article/bc995677d94eb372PharmaRadar360en2026-04-21T08:07:52.000ZRecentring Sites: The human factors slowing study start-up and how to resolve themhttps://www.pharmaradar360.com/article/2aa7b1ad120ea92ePharmaRadar360en2026-04-21T08:00:04.000ZMarking and assessment boycotthttps://www.pharmaradar360.com/article/cae2edb8015be425PharmaRadar360en2026-04-21T07:55:00.000ZGroundbreaking bowel cancer trial follow-up shows zero relapseshttps://www.pharmaradar360.com/article/d3139447e123e4e8PharmaRadar360en2026-04-21T07:45:11.000ZUniklinika plädieren für tragfähiges Gesamtkonzepthttps://www.pharmaradar360.com/article/9d08002a8fa2bc70PharmaRadar360en2026-04-21T07:39:00.000ZDeutsches Zentrum für Kinder- und Jugendgesundheit (DZKJ)https://www.pharmaradar360.com/article/19583cfb6926b4fcPharmaRadar360en2026-04-21T07:21:39.000ZInaugural Lecture: Prof Ashenafi Beyene Fantahttps://www.pharmaradar360.com/article/f25774ad94b6aec6PharmaRadar360en2026-04-21T07:00:00.000ZDr. Davies updates campus happenings, new process initiativehttps://www.pharmaradar360.com/article/cad8f0658d5ab553PharmaRadar360en2026-04-21T06:59:00.000ZKeith Olsen, PharmD, looks back fondly on his careerhttps://www.pharmaradar360.com/article/57b158c18c9cd949PharmaRadar360en2026-04-21T06:58:00.000ZUNMC resident’s rotation in India proves eye-openinghttps://www.pharmaradar360.com/article/64ceeaae391ec8ebPharmaRadar360en2026-04-21T06:54:00.000ZNew UNMC intranet design debuts todayhttps://www.pharmaradar360.com/article/8d133f03dfaeafe0PharmaRadar360en2026-04-21T06:30:47.000ZBuckinghamshire trust signs System C deal for AI-scribing in EPRhttps://www.pharmaradar360.com/article/50f416c0d6fc2994PharmaRadar360en2026-04-21T06:10:00.000Zbio:cap 2026: Wo KI auf Life-Science triffthttps://www.pharmaradar360.com/article/0e2c0574e161c466PharmaRadar360en2026-04-21T06:02:35.000ZAvacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platformhttps://www.pharmaradar360.com/article/f4f463a408a85c8bPharmaRadar360en2026-04-21T06:00:00.000ZParlons Santé !, la lettre d’info qui prend soin de voushttps://www.pharmaradar360.com/article/dd974e71cc5328b2PharmaRadar360en2026-04-21T05:28:00.000ZFAIR4Rare abgeschlossenhttps://www.pharmaradar360.com/article/2d05e373d46ccd61PharmaRadar360en2026-04-21T05:01:35.000ZInvestors Sound Off on BCI Hype, Regulatory Risk, and the AI Gold Rushhttps://www.pharmaradar360.com/article/0fc22983a78f6de5PharmaRadar360en2026-04-21T05:00:00.000ZFDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupushttps://www.pharmaradar360.com/article/9b4be12eab087cf0PharmaRadar360en2026-04-21T04:00:00.000Z#RASSEGNASTAMPA. I trattamenti innovativi per gli occhi: Tommaso Nuzzo a TG4 Medicinahttps://www.pharmaradar360.com/article/af33e43f71631351PharmaRadar360en2026-04-21T03:47:00.000ZGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failurehttps://www.pharmaradar360.com/article/de8f27079a21caf5PharmaRadar360en2026-04-21T03:37:13.000ZFDA’s Pep(tide) Rally! What Compounders and Industry Need to Know (Post 1 of 2)https://www.pharmaradar360.com/article/da8a4abfa1c8637bPharmaRadar360en2026-04-21T03:26:42.000ZTourists more likely to undergo unnecessary imaging in the EDhttps://www.pharmaradar360.com/article/b2cb948acfdb826aPharmaRadar360en2026-04-21T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Infliximab (genetical recombination) and biosimilars , etc. postedhttps://www.pharmaradar360.com/article/33934394b10ed173PharmaRadar360en2026-04-21T02:40:36.000ZCleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblieshttps://www.pharmaradar360.com/article/dc78d9a418498b79PharmaRadar360en2026-04-21T02:36:52.000ZHospital system pours $20M into expanding imaging, oncology serviceshttps://www.pharmaradar360.com/article/8c2df7cf2dc7519ePharmaRadar360en2026-04-21T02:22:00.000ZHow to Choose a Financial Planner Without Regret: A Practical Guide for Pharmacistshttps://www.pharmaradar360.com/article/2e9865bff6959a87PharmaRadar360en2026-04-21T02:15:28.000Z1枚の眼底写真から体の年齢を示す「網膜年齢」を推定するAIを開発-糖尿病・心疾患・脳卒中との関連を確認-https://www.pharmaradar360.com/article/a114240f130970d9PharmaRadar360en2026-04-21T01:57:28.000ZCRISPR Screens Map Human T‑Cell Genes That Promote or Block HIV Infectionhttps://www.pharmaradar360.com/article/01d636659d58a46cPharmaRadar360en2026-04-21T01:57:00.000ZNWA Heart Walk spotlights how heart disease can strike at any agehttps://www.pharmaradar360.com/article/d7b38cfa80be5f79PharmaRadar360en2026-04-21T01:31:59.000ZTEMPO 420 SChttps://www.pharmaradar360.com/article/c9acd1f44286fed9PharmaRadar360en2026-04-21T01:31:36.000ZTEMPO 420 SChttps://www.pharmaradar360.com/article/d240bd3023e0f7ecPharmaRadar360en2026-04-21T01:00:00.000ZEfficacy of Lactic Acid Bacterium ONRICb0240 Against Gingivitis ConfirmedA collaborative study with the Institute of Science Tokyo brings new hope for oral carehttps://www.pharmaradar360.com/article/1c2c8d1bb8df8737PharmaRadar360en2026-04-21T00:19:56.000ZPreclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myelomahttps://www.pharmaradar360.com/article/5678e64a3b74273ePharmaRadar360en2026-04-21T00:00:00.000ZUpdate on the Phase 3 STAR-121 Study of Anti-TIGIT Antibody Domvanalimab and Anti-PD-1 Antibody Zimberelimab in Non-Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/1f98949f9a9a281dPharmaRadar360en2026-04-21T00:00:00.000ZGenomic approaches for understanding the evolution of the human brainhttps://www.pharmaradar360.com/article/9d7ff018e805f381PharmaRadar360en2026-04-21T00:00:00.000ZConstituent-constrained word prediction during language comprehensionhttps://www.pharmaradar360.com/article/7aecaf0d00785a40PharmaRadar360en2026-04-21T00:00:00.000ZShow us the evidence for the value of medical AIhttps://www.pharmaradar360.com/article/6b9c077ea5eaa286PharmaRadar360en2026-04-21T00:00:00.000ZModifying exposure to plastic-associated chemicals in daily livinghttps://www.pharmaradar360.com/article/3b2d2a27281a6858PharmaRadar360en2026-04-21T00:00:00.000ZWearables as personal health custodianshttps://www.pharmaradar360.com/article/a2553bc7ec5c03f9PharmaRadar360en2026-04-21T00:00:00.000ZThe Q-MONSTAR consortium: advancing fault-tolerant quantum computing for precision oncologyhttps://www.pharmaradar360.com/article/0024ce565a9f7801PharmaRadar360en2026-04-21T00:00:00.000ZEpigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposurehttps://www.pharmaradar360.com/article/e91948ff50e9eaa3PharmaRadar360en2026-04-21T00:00:00.000ZThe patient is now in the roomhttps://www.pharmaradar360.com/article/b8e8d41492e88678PharmaRadar360en2026-04-21T00:00:00.000ZIs AI actually improving healthcare?https://www.pharmaradar360.com/article/9ff6750fe633e699PharmaRadar360en2026-04-21T00:00:00.000ZLow-plastic diet and urinary levels of plastic-associated phthalates and bisphenols: the randomized controlled PERTH Trialhttps://www.pharmaradar360.com/article/c09958c7266a1794PharmaRadar360en2026-04-21T00:00:00.000ZAI doom warnings are getting louder. Are they realistic?https://www.pharmaradar360.com/article/1fc9a9dd5e7b66d0PharmaRadar360en2026-04-21T00:00:00.000ZPersonalized CRISPR therapies could soon reach thousands — here’s howhttps://www.pharmaradar360.com/article/2a057ac6aa667668PharmaRadar360en2026-04-21T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/6ac8dd5904f0a0bcPharmaRadar360en2026-04-21T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/1434e47b63a03876PharmaRadar360en2026-04-21T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/af08078a9c4d3e0aPharmaRadar360en2026-04-21T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/39b65de670d64f29PharmaRadar360en2026-04-21T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/4cd4e09834cdb291PharmaRadar360en2026-04-21T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/38636313998662d9PharmaRadar360en2026-04-21T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/67ec1d241e468a92PharmaRadar360en2026-04-21T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/a0a77c6c34162e9fPharmaRadar360en2026-04-21T00:00:00.000Zlegal update regarding risdiplamhttps://www.pharmaradar360.com/article/52ccd805fbfd4c6ePharmaRadar360en2026-04-21T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/0ab0e36607484f3dPharmaRadar360en2026-04-21T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/cd49e8bc118bd19cPharmaRadar360en2026-04-21T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/54eeb74eedafdd20PharmaRadar360en2026-04-21T00:00:00.000Z6203https://www.pharmaradar360.com/article/ef785fa535cb7e21PharmaRadar360en2026-04-21T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/13230de8f1e5eeecPharmaRadar360en2026-04-21T00:00:00.000ZTidiga varningssignaler vid hjärninfektion hos barn identifieradehttps://www.pharmaradar360.com/article/7987804b30a6cf16PharmaRadar360en2026-04-21T00:00:00.000ZSocialt stöd kan hjälpa äldre att förbli självständiga trots kognitiv försämringhttps://www.pharmaradar360.com/article/823951478ae53302PharmaRadar360en2026-04-21T00:00:00.000ZNu enklare att hitta rätt innovationsstöd vid KIhttps://www.pharmaradar360.com/article/d0b09755bd7fddcePharmaRadar360en2026-04-21T00:00:00.000ZKarl-Johan Malmberg tilldelas Tobiaspriset 2026https://www.pharmaradar360.com/article/f6fc52d67bf944cbPharmaRadar360en2026-04-21T00:00:00.000ZBarndomstrauman kopplas till svårbehandlad depressionhttps://www.pharmaradar360.com/article/059476b2ccc5eddePharmaRadar360en2026-04-20T23:30:00.000ZU.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibilityhttps://www.pharmaradar360.com/article/b4b3cb5c75ef1b96PharmaRadar360en2026-04-20T23:10:00.000ZSGLT2 Inhibitors Did Not Appear to Alter Risk of Parkinson Disease Onsethttps://www.pharmaradar360.com/article/093768eb8fcaa9b3PharmaRadar360en2026-04-20T22:33:00.000ZReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejectionhttps://www.pharmaradar360.com/article/8023c35cdfbed295PharmaRadar360en2026-04-20T22:00:00.000ZIdentifican un biomarcador que mejora la predicción del riesgo en una forma grave de insuficiencia cardiacahttps://www.pharmaradar360.com/article/d82c3afa3f6d3c98PharmaRadar360en2026-04-20T21:55:00.000Z[15.05] 30 anni dalla nascita di SVSeD: esperienze a confronto 30 anni dalla nascita della legge 66 del 1996 sulla violenza sessualehttps://www.pharmaradar360.com/article/9494c776347cce04PharmaRadar360en2026-04-20T21:53:13.000ZSafely Extending Treatment in Alveolar Soft Part Sarcomahttps://www.pharmaradar360.com/article/0dc8268448fd948aPharmaRadar360en2026-04-20T21:44:59.000ZCannabis and Driving? Studies Reveal Big Riskshttps://www.pharmaradar360.com/article/7d9a2050cfeb4ae9PharmaRadar360en2026-04-20T21:29:22.000ZDay of Excellence in Academics 2026 – Event Recaphttps://www.pharmaradar360.com/article/d3beafb883514d06PharmaRadar360en2026-04-20T21:20:24.000ZProtocol Amendments Don’t Have to Create Chaoshttps://www.pharmaradar360.com/article/054113a08c733dc5PharmaRadar360en2026-04-20T21:00:44.000ZCU Anschutz Launches Clinical Trial for CAPD Therapy That Reversed Hearing Loss in Modelshttps://www.pharmaradar360.com/article/93a0335cef747b82PharmaRadar360en2026-04-20T20:52:16.000ZStudy Suggests That Strategic Wikipedia Engagement Enhances Scientific Visibility, Highlighting New Imperatives for AI-Era Information Accesshttps://www.pharmaradar360.com/article/3ac4cfaac50b6234PharmaRadar360en2026-04-20T20:37:37.000ZTim Cook to become Apple Executive Chairman John Ternus to become Apple CEOhttps://www.pharmaradar360.com/article/7f148a7f6b549b07PharmaRadar360en2026-04-20T20:31:30.000ZJohny Srouji named Apple’s Chief Hardware Officerhttps://www.pharmaradar360.com/article/26c614a6d651449cPharmaRadar360en2026-04-20T20:28:23.000ZSynthetic Biology and Tissue Engineering Grow Liver Tissue In‑Bodyhttps://www.pharmaradar360.com/article/63a839898a447fd0PharmaRadar360en2026-04-20T20:15:40.000ZSponsor’s Guide to IRB Approval: What Every Sponsor Needs to Know Before Submitting a Studyhttps://www.pharmaradar360.com/article/38fde58e2d23cbc7PharmaRadar360en2026-04-20T19:49:00.000ZTwo Colorado changemakers triumph in competition to end cardiovascular diseasehttps://www.pharmaradar360.com/article/f0009959bd2f2448PharmaRadar360en2026-04-20T19:47:15.000ZQ&A with Advarra’s Director of Training in IRB Services Lori Younghttps://www.pharmaradar360.com/article/a300d67635488fa1PharmaRadar360en2026-04-20T19:47:08.000ZTransforming APPEs: How Self-Reflection Builds Pharmacist Identityhttps://www.pharmaradar360.com/article/209e51b2c88a4fafPharmaRadar360en2026-04-20T19:42:08.000ZInside AD/PD 2026: Emerging Breakthroughs in Alzheimer’s and Parkinson’shttps://www.pharmaradar360.com/article/6685e4ac692d0eebPharmaRadar360en2026-04-20T19:36:28.000ZCollaborating with a purposehttps://www.pharmaradar360.com/article/55d43a43ca969299PharmaRadar360en2026-04-20T19:30:00.000ZReboxetine Reduces Overall Narcolepsy Symptom Severity and Improves EDS, Mood-Related Symptomshttps://www.pharmaradar360.com/article/b00ce74ec8659d2dPharmaRadar360en2026-04-20T19:23:20.000ZThe Omnichannel Gap: Building the CRM of the Future for Patient Serviceshttps://www.pharmaradar360.com/article/f2a3f3f101955fb9PharmaRadar360en2026-04-20T19:23:20.000ZThe Omnichannel Gap: Building the CRM of the Future for Patient Serviceshttps://www.pharmaradar360.com/article/884787758e2ca7a1PharmaRadar360en2026-04-20T19:11:11.000ZPfizer at a Crossroads: Leadership, Strategy, and the Risk of a Narrative Cliffhttps://www.pharmaradar360.com/article/4a429184964c98fbPharmaRadar360en2026-04-20T19:04:11.000ZTrump, FDA plan to expedite psychedelic developmenthttps://www.pharmaradar360.com/article/6312ffa662aa1ac3PharmaRadar360en2026-04-20T18:33:25.000ZTrump Executive Order Seeks to Accelerate Psychedelic Drug Development for PTSD, Addictionhttps://www.pharmaradar360.com/article/7e8095df97ec9bb1PharmaRadar360en2026-04-20T18:24:47.000ZNovartis cuts two programs in cancer-related blood clotshttps://www.pharmaradar360.com/article/21086707742dccdePharmaRadar360en2026-04-20T18:18:51.000ZRESPC this student group’s workhttps://www.pharmaradar360.com/article/a5d9f3d0f14260ecPharmaRadar360en2026-04-20T18:14:40.000ZPharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeuticshttps://www.pharmaradar360.com/article/357684fff4f54858PharmaRadar360en2026-04-20T18:11:32.000ZPediatric Plating Platform™ | Small – Minihttps://www.pharmaradar360.com/article/2d2f8bf82f3e460ePharmaRadar360en2026-04-20T18:06:21.000ZFDA ESG Integration: Why Now Is the Time to Move Beyond Manual Submissionshttps://www.pharmaradar360.com/article/4132d96a19c457bcPharmaRadar360en2026-04-20T18:03:55.000ZLilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipelinehttps://www.pharmaradar360.com/article/936d28f80286e71dPharmaRadar360en2026-04-20T17:44:09.000ZWhere Study Simulation Fits in Clinical Trialshttps://www.pharmaradar360.com/article/037257ee2b518fcbPharmaRadar360en2026-04-20T17:29:00.000Z'Hospitals adverse to transparency'—clashing industry groups spar on mulligan 340B rebate pilothttps://www.pharmaradar360.com/article/8322212301e7ff4aPharmaRadar360en2026-04-20T17:15:00.000ZHow a Hidden Molecular Feedback Loop Helps Colorectal Cancer Hide from the Immune Systemhttps://www.pharmaradar360.com/article/a1cbcc971510fa93PharmaRadar360en2026-04-20T17:09:35.000ZAACR 2026: Cancers of Unknown Primary Identified by DNA Methylation AI Modelhttps://www.pharmaradar360.com/article/0dd2a16e1ea53674PharmaRadar360en2026-04-20T17:01:56.000ZPresidentes de la UNLPhttps://www.pharmaradar360.com/article/2bad20b393bbc2d1PharmaRadar360en2026-04-20T16:42:11.000ZHow Employers Support Lower-Waged Workers’ Access to Health Insurance Optionshttps://www.pharmaradar360.com/article/4d1f45c486e95330PharmaRadar360en2026-04-20T16:39:38.000ZErgomed Clinical Research Named Finalist in Fierce Outsourcing Awards 2026 for “Clinical Trial Management”https://www.pharmaradar360.com/article/2e32138bc1efb6bfPharmaRadar360en2026-04-20T16:27:00.000ZLower Drug Prices Won’t Fix America’s Pharmacy Crisishttps://www.pharmaradar360.com/article/b46fc8da158697efPharmaRadar360en2026-04-20T16:21:00.000ZRespecting Patient Curiosity in the Age of AI: How Oncology Teams Can Respond to Unproven Cancer Therapieshttps://www.pharmaradar360.com/article/34fd3641d187989dPharmaRadar360en2026-04-20T16:16:57.000ZUNC-Chapel Hill Army ROTC earns prestigious MacArthur Awardhttps://www.pharmaradar360.com/article/d39baf918ebc03cdPharmaRadar360en2026-04-20T16:03:50.000ZMedical Summer School 2026 – University of Rostock (Alemania)https://www.pharmaradar360.com/article/c1dc32aabfc3c3caPharmaRadar360en2026-04-20T16:03:31.000ZAAN 2026: Phase III success for azetukalner in focal epilepsy paves approval pathhttps://www.pharmaradar360.com/article/2c349b6d633f5dafPharmaRadar360en2026-04-20T16:00:00.000ZXuanzhu shares dip despite phase III ALK inhibitor datahttps://www.pharmaradar360.com/article/8aa35770f4fcd013PharmaRadar360en2026-04-20T16:00:00.000ZPsychedelic space expanding on Trump’s EOhttps://www.pharmaradar360.com/article/85a669caf8b6e0d9PharmaRadar360en2026-04-20T15:56:37.000ZBritish patients risking “fake” weight loss drugs, despite safety concerns, survey sayshttps://www.pharmaradar360.com/article/0f9cb9c49dfbd400PharmaRadar360en2026-04-20T15:51:00.000ZMerck partner reveals bispecific data; Biogen pays $100M for antibody rightshttps://www.pharmaradar360.com/article/101794549ad8d115PharmaRadar360en2026-04-20T15:43:14.000ZBecas AUIP – Doctorado en la Universidad de Murcia 2026https://www.pharmaradar360.com/article/63cb47d3262d483bPharmaRadar360en2026-04-20T15:37:54.000ZCátedras Libreshttps://www.pharmaradar360.com/article/33e2ac324012b545PharmaRadar360en2026-04-20T15:31:23.000ZBuprenorphine and Methadone in Pregnancy: What the Latest Data Show About Child Developmenthttps://www.pharmaradar360.com/article/fbd5fcc570048a7ePharmaRadar360en2026-04-20T15:22:32.000ZBoletín de Posgradohttps://www.pharmaradar360.com/article/4f748bfe2670aa34PharmaRadar360en2026-04-20T15:15:00.000ZA look inside Highmark and Spring Health's mental well-being partnershiphttps://www.pharmaradar360.com/article/008eceb902bd0590PharmaRadar360en2026-04-20T15:10:06.000ZGut microbiome changes may signal Parkinson’s disease riskhttps://www.pharmaradar360.com/article/f90691e763ced065PharmaRadar360en2026-04-20T15:03:50.000Z30 anni di Humanitas: scienza, responsabilità e innovazione per la sanità del Paesehttps://www.pharmaradar360.com/article/b15099ad5969634aPharmaRadar360en2026-04-20T15:00:54.000ZHow genomics clarifies a complex Campylobacter picturehttps://www.pharmaradar360.com/article/8811e03f59736b14PharmaRadar360en2026-04-20T14:55:00.000ZCVS, Mass General Brigham primary care deal would increase annual care spending by $40M, report predictshttps://www.pharmaradar360.com/article/169b963095d1e623PharmaRadar360en2026-04-20T14:49:30.000ZKelonia investor Venrock will clear a 45-fold return on startup's sale to Lillyhttps://www.pharmaradar360.com/article/10dc7309e28704dcPharmaRadar360en2026-04-20T14:45:13.000ZBoehringer Ingelheim to expand its AI footprint in UK, in £150M investmenthttps://www.pharmaradar360.com/article/9dc17a9c5c217af7PharmaRadar360en2026-04-20T14:41:42.000ZBiotech has become a good news story. Let the sun shinehttps://www.pharmaradar360.com/article/1cb75d99f66f4e08PharmaRadar360en2026-04-20T14:37:06.000ZNovo Nordisk to seek oral sickle cell therapy approval after Phase III victoryhttps://www.pharmaradar360.com/article/5a21c44eb42515d9PharmaRadar360en2026-04-20T14:36:09.000ZBoehringer Ingelheim launches AI centre in Londonhttps://www.pharmaradar360.com/article/d912ce89e745d176PharmaRadar360en2026-04-20T14:35:08.000ZGilead declines another Arcus option after Phase 3 TIGIT failhttps://www.pharmaradar360.com/article/f4d776df16271966PharmaRadar360en2026-04-20T14:25:00.000ZDelaware nurse practitioner raises awareness and funds to end women’s No. 1 health threathttps://www.pharmaradar360.com/article/33cb6de55b2620efPharmaRadar360en2026-04-20T14:24:11.000ZPresident Trump Signs Executive Order to Accelerate FDA Reviews for Psychedelic Drugshttps://www.pharmaradar360.com/article/0452232dd16c4aebPharmaRadar360en2026-04-20T14:17:50.000ZDecision: Marketing authorisations Granted in 2026https://www.pharmaradar360.com/article/1bff7f69ca8ab7dcPharmaRadar360en2026-04-20T14:06:23.000ZUnity Health Toronto strengthens coordinated care for patients with high-risk pregnancieshttps://www.pharmaradar360.com/article/6c1e344f88058cd3PharmaRadar360en2026-04-20T14:00:00.000ZAAN 2026: How Biological Sex and Gender Independently Shape TBI Survival and Recoveryhttps://www.pharmaradar360.com/article/813a084f11cc8eb1PharmaRadar360en2026-04-20T14:00:00.000ZWe need to correct the wide-spread omission of equal contribution in article indexinghttps://www.pharmaradar360.com/article/18faab6d345d893fPharmaRadar360en2026-04-20T13:48:35.000ZAllogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026https://www.pharmaradar360.com/article/2e558add97dfe4baPharmaRadar360en2026-04-20T13:36:18.000ZOutsourcing in Clinical Trials UK & Ireland 2026https://www.pharmaradar360.com/article/f77d75564cc26c88PharmaRadar360en2026-04-20T13:34:00.000ZSentirsi ancora Umani. Giornata dei donatori di organi e tessuti al Policlinico di Milanohttps://www.pharmaradar360.com/article/8cb3f5c3bd2ff25bPharmaRadar360en2026-04-20T13:33:33.000ZBeyond GLP-1Rs: emerging targets poised to gain share of obesity markethttps://www.pharmaradar360.com/article/9a47b562dd203288PharmaRadar360en2026-04-20T13:32:18.000ZPharmaceutical cleaning solutions and depyrogenation tunnelshttps://www.pharmaradar360.com/article/d3f578e7a7f38d39PharmaRadar360en2026-04-20T13:31:19.000ZReunión del Comité de Medicamentos de Uso Humano de abril de 2026https://www.pharmaradar360.com/article/b3c02ae2fcb2108cPharmaRadar360en2026-04-20T13:30:34.000ZEli Lilly Enters $7 Billion Agreement to Acquire Kelonia Therapeuticshttps://www.pharmaradar360.com/article/58526befc5f05bafPharmaRadar360en2026-04-20T13:30:00.000ZAAN 2026: Rituximab vs. Approved NMOSD Therapies, What the SPHERES Registry Reveals About Real-World Treatment Gapshttps://www.pharmaradar360.com/article/d9990d62bd98dbc6PharmaRadar360en2026-04-20T13:25:03.000ZLilly to buy Kelonia for $3.25B upfront, underlining its in vivo CAR-T strategyhttps://www.pharmaradar360.com/article/137d7987a186a863PharmaRadar360en2026-04-20T13:24:00.000ZAACR: Endeavoring to go global, Zai Lab offers reality check on China’s biotech ascenthttps://www.pharmaradar360.com/article/befa065fdce6a371PharmaRadar360en2026-04-20T13:17:58.000ZThompson Paine’s Carolina roots help shape AI’s futurehttps://www.pharmaradar360.com/article/d8ecb2a1113dc028PharmaRadar360en2026-04-20T13:14:10.000ZMoving Towards Inclusive History Education?https://www.pharmaradar360.com/article/7e4929ea525481abPharmaRadar360en2026-04-20T13:07:02.000ZLive Updates From the AACR Annual Meeting 2026: Monday, April 20https://www.pharmaradar360.com/article/a64c28f588244b52PharmaRadar360en2026-04-20T13:03:25.000ZPodcast: CEO Heltzen @ Executive Insights for Life Sciences Innovatorshttps://www.pharmaradar360.com/article/ff99cd996620e8a5PharmaRadar360en2026-04-20T13:02:00.000ZNew collaboration addresses statewide social worker shortagehttps://www.pharmaradar360.com/article/0bfe9ea016219e9cPharmaRadar360en2026-04-20T13:00:43.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/ccb207968e88769ePharmaRadar360en2026-04-20T13:00:00.000ZLilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapieshttps://www.pharmaradar360.com/article/a63563cae5002839PharmaRadar360en2026-04-20T12:48:52.000ZWinter School on Tropical Diseases – UNESP (Brasil)https://www.pharmaradar360.com/article/3aa3d738326465daPharmaRadar360en2026-04-20T12:41:00.000Z#NEWSLETTER. DottoressaV - Conservazione degli ovociti: riflessioni a mente freddahttps://www.pharmaradar360.com/article/6a543ae7e4f446d7PharmaRadar360en2026-04-20T12:39:50.000ZNeurochirurgie adulte : les trois domaines d'expertise | Parlons santé !https://www.pharmaradar360.com/article/55d7eecce9be3ab5PharmaRadar360en2026-04-20T12:39:27.000ZGerresheimer & Milliken Partner to Advance Performance & Protection With LeneX UltraGuard Technologyhttps://www.pharmaradar360.com/article/11db7550f587d2e3PharmaRadar360en2026-04-20T12:34:32.000ZDecision: Parallel import licences granted in 2026https://www.pharmaradar360.com/article/880068dedc3f35edPharmaRadar360en2026-04-20T12:33:06.000Zmenu - U1355 – RAMO-IT - Radiothérapie Moléculaire et Innovations Thérapeutiqueshttps://www.pharmaradar360.com/article/44941b01523e19a1PharmaRadar360en2026-04-20T12:30:49.000ZAI tool allows a million patients to book appointments via NHS Apphttps://www.pharmaradar360.com/article/e1093e39d1a1b702PharmaRadar360en2026-04-20T12:30:46.000ZDecoding Resistance to Targeted Therapy via New Cancer Modelshttps://www.pharmaradar360.com/article/44410653d29f6b93PharmaRadar360en2026-04-20T12:24:33.000ZHongos: el superalimento que pide precauciónhttps://www.pharmaradar360.com/article/ce60cacaf6f62364PharmaRadar360en2026-04-20T12:24:07.000ZBecas internacionales de la Subsecretaría de Relaciones Internacionales e Interjurisdiccionales de la Provincia de Bs. Ashttps://www.pharmaradar360.com/article/b78d3662eb5730d9PharmaRadar360en2026-04-20T12:16:00.000ZHippocratic AI rolls out 2 new tools aimed at expanding clinical access, improving nurse workflowhttps://www.pharmaradar360.com/article/6028cb95ffb80079PharmaRadar360en2026-04-20T12:15:59.000ZWhat Makes Real-World Evidence Credible? Insights from Academic Researchhttps://www.pharmaradar360.com/article/5cb440d12a7304a3PharmaRadar360en2026-04-20T12:06:09.000ZClass 2 Medicines Recall: Crescent Pharma Limited, Ramipril 10mg capsules, EL(26)A/19https://www.pharmaradar360.com/article/2ab99e570169c33cPharmaRadar360en2026-04-20T12:00:35.000ZU1355 RAMO-IT - Radiothérapie Moléculaire et Innovations Thérapeutiques - membres de l’unitéhttps://www.pharmaradar360.com/article/37f75189fb9f00a3PharmaRadar360en2026-04-20T12:00:00.000ZKyoto University releases "Creating our future together: KyotoU Future Commons"https://www.pharmaradar360.com/article/2cb3771be9720d43PharmaRadar360en2026-04-20T12:00:00.000ZBlenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myelomahttps://www.pharmaradar360.com/article/175f8d3a7589f13ePharmaRadar360en2026-04-20T12:00:00.000ZAmneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®https://www.pharmaradar360.com/article/feca07158494c8faPharmaRadar360en2026-04-20T11:53:19.000ZThe capsule formula fueling steady growthhttps://www.pharmaradar360.com/article/0389cc3d2bc456ebPharmaRadar360en2026-04-20T11:52:01.000ZFernando Tauber, Doctor Honoris Causa de la Universidad Nacional de La Pampahttps://www.pharmaradar360.com/article/ac1ed39936d49e2ePharmaRadar360en2026-04-20T11:51:16.000ZU1355 Radiothérapie Moléculaire et Innovations Thérapeutiques - publicationshttps://www.pharmaradar360.com/article/6bb235d9acde96a7PharmaRadar360en2026-04-20T11:50:49.000ZMaidontuotannon hiilijalanjälki mahdollisesti oletettua suurempihttps://www.pharmaradar360.com/article/803f53d3d7a6c33aPharmaRadar360en2026-04-20T11:50:00.000ZMedtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular diseasehttps://www.pharmaradar360.com/article/622db0788bc2a07dPharmaRadar360en2026-04-20T11:47:47.000ZKI-gestütztes Projekt erforscht Zusammenhang zwischen Darmerkrankungen und Parkinson-Krankheithttps://www.pharmaradar360.com/article/4199bfff3a62f32dPharmaRadar360en2026-04-20T11:33:00.000ZIn Connecticut, doctors now sue patients most over medical bills, surpassing hospitalshttps://www.pharmaradar360.com/article/132068fcec65236fPharmaRadar360en2026-04-20T11:32:12.000ZNektar’s long-term mid-stage alopecia data fuel Phase 3 planshttps://www.pharmaradar360.com/article/99ec70e33abe3ea6PharmaRadar360en2026-04-20T11:30:00.000Z‘Football is becoming a sport for the elite’https://www.pharmaradar360.com/article/e8eb108d919f0ee5PharmaRadar360en2026-04-20T11:28:39.000ZFernando Tauber Presidente de la UNLPhttps://www.pharmaradar360.com/article/8d6a3204b9da73a7PharmaRadar360en2026-04-20T11:25:52.000ZConcursos Presidenciahttps://www.pharmaradar360.com/article/34da2fb48aae2290PharmaRadar360en2026-04-20T11:22:59.000ZConcursos NoDocenteshttps://www.pharmaradar360.com/article/a0ea77663dc2dde6PharmaRadar360en2026-04-20T11:22:53.000ZMaterial de Lecturahttps://www.pharmaradar360.com/article/daeaaf4bae315f4aPharmaRadar360en2026-04-20T11:20:00.000ZCocaine pollution gives salmon wanderlusthttps://www.pharmaradar360.com/article/ed151eb0f2546221PharmaRadar360en2026-04-20T11:14:27.000ZThis missing vitamin could stop cancer cells in their trackshttps://www.pharmaradar360.com/article/e5a432344eae0062PharmaRadar360en2026-04-20T11:00:00.000ZThis disabled parrot has become king by learning to ‘joust’https://www.pharmaradar360.com/article/84e5256e6beb4e0dPharmaRadar360en2026-04-20T10:57:44.000Z“Skin patch helped me spot lung rejection” says beneficiaryhttps://www.pharmaradar360.com/article/70fe60eae9cc74d1PharmaRadar360en2026-04-20T10:53:54.000ZThis simple 3-amino acid trick boosts mRNA therapy 20-foldhttps://www.pharmaradar360.com/article/988bc66ff620e495PharmaRadar360en2026-04-20T10:48:00.000ZFDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancerhttps://www.pharmaradar360.com/article/10068426bb62b7f9PharmaRadar360en2026-04-20T10:46:34.000ZNovo Nordisk’s sickle cell therapy hits in Phase 3, but data lag expectationshttps://www.pharmaradar360.com/article/0bd2edd1d38e5c5cPharmaRadar360en2026-04-20T10:44:47.000ZNCT/UCC- Patiententag 2026https://www.pharmaradar360.com/article/8c7c6adf00e66b00PharmaRadar360en2026-04-20T10:31:36.000ZTrump backs psychedelics for mental health in new executive orderhttps://www.pharmaradar360.com/article/799bdda0462e00e0PharmaRadar360en2026-04-20T10:30:55.000ZTrump backs psychedelics for mental health in new executive orderhttps://www.pharmaradar360.com/article/7ff622eae51020c2PharmaRadar360en2026-04-20T10:21:00.000ZSanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspikehttps://www.pharmaradar360.com/article/8f645f4436f843ecPharmaRadar360en2026-04-20T10:16:55.000ZACI’s 2nd Annual Summit on GLP-1 Law & Policyhttps://www.pharmaradar360.com/article/7376807384c7a528PharmaRadar360en2026-04-20T10:08:00.000ZHelsinki Legal History Series: Karolina Stenlundhttps://www.pharmaradar360.com/article/06b4f59dcec26115PharmaRadar360en2026-04-20T10:00:57.000ZNHS App ‘not improving patients’ views on NHS admin’https://www.pharmaradar360.com/article/5375f1519d2c94a8PharmaRadar360en2026-04-20T10:00:00.000ZAddressing Regulatory Issues and the Biosimilar Void: Q&A with Thomas Newcomerhttps://www.pharmaradar360.com/article/c6e7555eae1c2e8dPharmaRadar360en2026-04-20T09:59:00.000ZLilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7Bhttps://www.pharmaradar360.com/article/4f0196e24093ca5aPharmaRadar360en2026-04-20T09:54:22.000ZAkamis Bio reports early data from NG-350A Phase Ib trialhttps://www.pharmaradar360.com/article/4100d0d6d0854575PharmaRadar360en2026-04-20T09:50:06.000ZUCB to purchase Neurona and NRTX-1001 for $1.15bnhttps://www.pharmaradar360.com/article/7c5e4316636df442PharmaRadar360en2026-04-20T09:47:15.000ZMagazine: Digital twins become the new battleground for CDMOshttps://www.pharmaradar360.com/article/453ca55be281a7d7PharmaRadar360en2026-04-20T09:37:00.000ZBiogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibodyhttps://www.pharmaradar360.com/article/1de7230ca01670c3PharmaRadar360en2026-04-20T09:32:00.000ZGenentech shifts Hemlibra marketing focus to patient stories as competition approacheshttps://www.pharmaradar360.com/article/6e45477cf6e46f39PharmaRadar360en2026-04-20T09:24:07.000ZNew Fellows selected to the Helsinki Collegium for Advanced Studieshttps://www.pharmaradar360.com/article/fcd8e5c94d0acf49PharmaRadar360en2026-04-20T09:18:21.000ZThe future of quality in CDMOs: The five-stage journey to an advanced Pharmaceutical Quality System (PQS)https://www.pharmaradar360.com/article/5de926b51be44ee2PharmaRadar360en2026-04-20T09:18:21.000ZThe future of quality in CDMOs: The five-stage journey to an advanced Pharmaceutical Quality System (PQS)https://www.pharmaradar360.com/article/85a17d836a0a7af0PharmaRadar360en2026-04-20T09:10:28.000ZHIKET session at the 5th ACCC Impact Weekhttps://www.pharmaradar360.com/article/e43e7e0e63f0764fPharmaRadar360en2026-04-20T09:01:36.000ZFour ways to build a secure and scalable CGT distribution networkhttps://www.pharmaradar360.com/article/9389f15ea2c67e21PharmaRadar360en2026-04-20T08:57:49.000ZUpdate after flooding on Stellenbosch campushttps://www.pharmaradar360.com/article/8dc7e8efa7e54b34PharmaRadar360en2026-04-20T08:52:00.000ZNeurogene hires new CCO as it eyes commercial future for its Rett gene therapyhttps://www.pharmaradar360.com/article/4973c8e821e61a7dPharmaRadar360en2026-04-20T08:43:49.000ZAgenus announces Phase II results from gastroesophageal cancer therapyhttps://www.pharmaradar360.com/article/94db5ab0d2be6cfcPharmaRadar360en2026-04-20T08:36:41.000ZLa UE abre consulta pública sobre la propuesta de restricción de las PFAShttps://www.pharmaradar360.com/article/bec2fd01e5c09043PharmaRadar360en2026-04-20T08:30:00.000ZNotice Regarding Determination of Issue Price, Selling Price and Other Mattershttps://www.pharmaradar360.com/article/0a01ac1b6ada1a1dPharmaRadar360en2026-04-20T08:29:08.000ZSuomen Tiedeseuran suuri palkinto 2026 professori Tuomas Heikkilällehttps://www.pharmaradar360.com/article/970449db38492752PharmaRadar360en2026-04-20T08:19:00.000ZBiovac nets $108M finance package to build Africa’s first fully integrated vaccine planthttps://www.pharmaradar360.com/article/3f2bb1b16ba551efPharmaRadar360en2026-04-20T08:15:02.000ZESR iGuide goes live at Hospital Universitari del Consorci Sanitari de Terrassa, enhancing Imaging Appropriatenesshttps://www.pharmaradar360.com/article/a9fe64707b66946ePharmaRadar360en2026-04-20T08:01:54.000ZHelsus Brown Bag lunch talk, by Alizée Ville, April 23rd 2026https://www.pharmaradar360.com/article/ce1518081e5b14e3PharmaRadar360en2026-04-20T07:58:53.000ZNew study shows editing grapevine DNA could boost resistance to disease and droughthttps://www.pharmaradar360.com/article/fa701a6fe0957153PharmaRadar360en2026-04-20T07:56:00.000ZNovo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 winhttps://www.pharmaradar360.com/article/c7448561f5c44fdaPharmaRadar360en2026-04-20T07:35:00.000ZTheramex exits self-regulatory body after ‘systemic’ compliance failureshttps://www.pharmaradar360.com/article/ccc9f5cf5a389c0bPharmaRadar360en2026-04-20T07:21:06.000ZGranuLean: high-quality granulation on a compact footprinthttps://www.pharmaradar360.com/article/a1df3ba640f028c6PharmaRadar360en2026-04-20T07:00:00.000ZStudy suggests link between prenatal exposure to certain medications and increased autism riskhttps://www.pharmaradar360.com/article/827fb1644e208eccPharmaRadar360en2026-04-20T07:00:00.000ZFondation HCL : soutenir des projets qui s’appuient sur l’IAhttps://www.pharmaradar360.com/article/e37b4cfc9776282bPharmaRadar360en2026-04-20T07:00:00.000ZHow Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordabilityhttps://www.pharmaradar360.com/article/ebde7386bb742f1bPharmaRadar360en2026-04-20T07:00:00.000ZImmunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Updatehttps://www.pharmaradar360.com/article/f6b177cc832337afPharmaRadar360en2026-04-20T07:00:00.000ZWhen the System Is the Treatment: Rethinking Nonpharmacologic Breakthroughs in Oncologyhttps://www.pharmaradar360.com/article/d939018acfef836cPharmaRadar360en2026-04-20T07:00:00.000ZVIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancerhttps://www.pharmaradar360.com/article/65e2428ed9fa0e65PharmaRadar360en2026-04-20T07:00:00.000ZBridging the Gap: What We Can Learn From LEAP-010 in Recurrent/Metastatic Head and Neck Cancerhttps://www.pharmaradar360.com/article/9549183bb21e8a73PharmaRadar360en2026-04-20T07:00:00.000ZReply to: “Limitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastases,” “Radiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trials,” and “Expanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastases”https://www.pharmaradar360.com/article/cbd5466887875f7dPharmaRadar360en2026-04-20T07:00:00.000ZGood Oncologist: Doctoring Lessons From the Art of Oncologyhttps://www.pharmaradar360.com/article/595da72bb40e50bfPharmaRadar360en2026-04-20T07:00:00.000ZTarget Trial Emulation for Regulatory and Clinical Decision Making in Cancerhttps://www.pharmaradar360.com/article/67d75d2ad8ba904aPharmaRadar360en2026-04-20T07:00:00.000ZExpanding Indications for Stereotactic Radiosurgery in Small Cell Lung Cancer With Brain Metastaseshttps://www.pharmaradar360.com/article/c623bb478afc735bPharmaRadar360en2026-04-20T07:00:00.000ZCALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancerhttps://www.pharmaradar360.com/article/eadc88d854c94be2PharmaRadar360en2026-04-20T07:00:00.000ZRadiosurgery for Small Cell Lung Cancer Brain Metastases: Comparing the JLGK0901 and BWH/DFCI Trialshttps://www.pharmaradar360.com/article/d327b09f29b934d9PharmaRadar360en2026-04-20T07:00:00.000ZLimitations in Study Design and Stratification in Phase II Stereotactic Radiosurgery Trial for Small Cell Lung Cancer Brain Metastaseshttps://www.pharmaradar360.com/article/88723aa4bbe5ada1PharmaRadar360en2026-04-20T07:00:00.000ZNivolumab ± Ipilimumab in Patients With Pretreated Advanced Neuroendocrine Carcinoma: The GCO-001 NIPINEC Randomized Phase II Trialhttps://www.pharmaradar360.com/article/3d61e20d24ffd678PharmaRadar360en2026-04-20T07:00:00.000ZEfficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)https://www.pharmaradar360.com/article/a6ac10042ad4f60fPharmaRadar360en2026-04-20T07:00:00.000ZFinancial Hardship Before Diagnosis: Influence on Late-Stage Cancer Presentation and the Role of Screeninghttps://www.pharmaradar360.com/article/8abb6594281a84bfPharmaRadar360en2026-04-20T07:00:00.000ZPembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Studyhttps://www.pharmaradar360.com/article/cd37aa9918e50d5bPharmaRadar360en2026-04-20T06:58:00.000ZUNMC Better Processes Initiative getting underwayhttps://www.pharmaradar360.com/article/564bcf6acc39ddf8PharmaRadar360en2026-04-20T06:56:00.000ZUNMC, Nebraska Medicine host For the Greater Good this weekhttps://www.pharmaradar360.com/article/7f658264fd0f23daPharmaRadar360en2026-04-20T06:54:00.000ZNew intranet design, other digital updateshttps://www.pharmaradar360.com/article/038850602c8b5357PharmaRadar360en2026-04-20T06:30:30.000ZTees, Esk and Wear Valleys signs contract to deploy Access EPRhttps://www.pharmaradar360.com/article/0dd67061d0314743PharmaRadar360en2026-04-20T06:28:09.000ZUnga idéer blev verklighet i Bengtsfors, Lysekil och Munkedalhttps://www.pharmaradar360.com/article/50b74eb9368ea262PharmaRadar360en2026-04-20T06:02:24.000ZResearch position at Suzuki Lab, Center for Cancer Immunotherapy and Immunobiology (CCII), Kyoto Universityhttps://www.pharmaradar360.com/article/85e90d299122ce80PharmaRadar360en2026-04-20T06:00:00.000ZVillage Alzheimer : un accompagnement qui améliore le devenir médical des résidentshttps://www.pharmaradar360.com/article/576e8b561dfef766PharmaRadar360en2026-04-20T05:53:00.000ZAgenus focuses on survival data as 0% response rate triggers primary misshttps://www.pharmaradar360.com/article/4420bfd9dd6a1c15PharmaRadar360en2026-04-20T04:53:00.000ZAstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD winhttps://www.pharmaradar360.com/article/a2f82590d80d96e9PharmaRadar360en2026-04-20T04:42:00.000ZTrump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcasterhttps://www.pharmaradar360.com/article/9076c6062bb963c4PharmaRadar360en2026-04-20T04:42:00.000ZTrump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcasterhttps://www.pharmaradar360.com/article/4b3830e48829b468PharmaRadar360en2026-04-20T04:22:00.000ZBayer falls short in bid to block J&J’s survival claims in prostate cancer clashhttps://www.pharmaradar360.com/article/ccae4d1ce95d2a20PharmaRadar360en2026-04-20T04:10:00.000ZOdyssey charts fresh voyage to public markets after abandoning IPO plans last yearhttps://www.pharmaradar360.com/article/9410d1151a55406dPharmaRadar360en2026-04-20T04:00:00.000ZUsing AI to Advance Validated Real-World Evidencehttps://www.pharmaradar360.com/article/bd719f23894657e7PharmaRadar360en2026-04-20T03:15:45.000ZEarly humans turned favored rock sites into toolmaking assembly lineshttps://www.pharmaradar360.com/article/bad301847a026aebPharmaRadar360en2026-04-20T03:00:00.000Z[KOKUSAI]A new page for the Regulatory Symposia has been launched.https://www.pharmaradar360.com/article/d9c93b498345950bPharmaRadar360en2026-04-20T02:51:00.000ZBiogen bullish on America with Durham Bulls team uphttps://www.pharmaradar360.com/article/8a030ac820d89a33PharmaRadar360en2026-04-20T02:46:00.000ZRoche boosts diagnostics offerings with $595M Saga buyouthttps://www.pharmaradar360.com/article/4dab8a1a56318cb2PharmaRadar360en2026-04-20T02:40:00.000ZAbbVie launches ‘PSO Done’ psoriasis campaign with cross-agency efforthttps://www.pharmaradar360.com/article/f7696a4e9bd22d6aPharmaRadar360en2026-04-20T02:23:50.000Z#AACR26: KRAS drugmakers take another, better swing at lung cancerhttps://www.pharmaradar360.com/article/ed0dee9ceb8d2c64PharmaRadar360en2026-04-20T02:00:00.000ZAgenda for May 2026 Pharmacology and Therapeutics advisory committee (PTAC) meetinghttps://www.pharmaradar360.com/article/dacc27d442d3ba67PharmaRadar360en2026-04-20T01:50:11.000ZFM DTS融合セミナー スタンフォード大学/MedVenture Partners, Inc 池野 文昭先生講演会開催のお知らせ（5/20開催）https://www.pharmaradar360.com/article/d27c42927f87891fPharmaRadar360en2026-04-20T01:45:33.000ZUCB plots epilepsy expansion with $650M Neurona cell therapy acquisitionhttps://www.pharmaradar360.com/article/8de956189b755751PharmaRadar360en2026-04-20T01:00:00.000ZScleral lens “Time XL” acquires approval in China - New option for patients with irregular cornea available in the Chinese market -https://www.pharmaradar360.com/article/c138d1dc858743edPharmaRadar360en2026-04-20T00:54:19.000ZOdyssey Therapeutics will try again to IPO, this time in a warmer markethttps://www.pharmaradar360.com/article/ec424640600c77d4PharmaRadar360en2026-04-20T00:00:00.000ZVMC Golf Raffle! — Petro's Chili & Chips™https://www.pharmaradar360.com/article/90b0d7bb8c3058dbPharmaRadar360en2026-04-20T00:00:00.000ZOtsuka Foods to Revise Prices of Some Products New Prices to Take Effect with Deliveries as of June 1, 2026https://www.pharmaradar360.com/article/bd620e7dc1074224PharmaRadar360en2026-04-20T00:00:00.000ZHeterogeneity and plasticity of cancer-associated fibroblastshttps://www.pharmaradar360.com/article/329e19c6ea58a526PharmaRadar360en2026-04-20T00:00:00.000ZHybrid supervised deep learning for lung adenocarcinoma diagnosis to optimize surgical strategieshttps://www.pharmaradar360.com/article/7e81346de3d7b2d4PharmaRadar360en2026-04-20T00:00:00.000ZComprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposinghttps://www.pharmaradar360.com/article/2545eec028367987PharmaRadar360en2026-04-20T00:00:00.000ZSafety considerations for cereblon-recruiting targeted protein degradershttps://www.pharmaradar360.com/article/d8ce2dce5089b37bPharmaRadar360en2026-04-20T00:00:00.000ZTarget identification and assessment in the era of AIhttps://www.pharmaradar360.com/article/8136396b7bd0041bPharmaRadar360en2026-04-20T00:00:00.000ZCorrection: Genetic mutations in HSV-1 replication-defective vectors: Implications for their safety in gene therapy applicationshttps://www.pharmaradar360.com/article/3b6f0319deb2b40bPharmaRadar360en2026-04-20T00:00:00.000ZDaily briefing: Immune cells have a surprising role in exercise endurancehttps://www.pharmaradar360.com/article/2002b0ba189ead4dPharmaRadar360en2026-04-20T00:00:00.000ZNo humans allowed: scientific AI agents get their own social networkhttps://www.pharmaradar360.com/article/dd7956c0b50f8f77PharmaRadar360en2026-04-20T00:00:00.000ZThrilling, frivolous, a waste: not everyone’s happy about the Artemis II Moon missionhttps://www.pharmaradar360.com/article/165e9316f8c6239ePharmaRadar360en2026-04-20T00:00:00.000ZGot bugs? Here’s how to catch the errors in your scientific softwarehttps://www.pharmaradar360.com/article/3f7225109ad84fe4PharmaRadar360en2026-04-20T00:00:00.000ZHow hidden contributions power modern researchhttps://www.pharmaradar360.com/article/367e5f6baca9aa50PharmaRadar360en2026-04-20T00:00:00.000Z‘Bat feast’ animal videos at African cave offer clues to how deadly viruses spreadhttps://www.pharmaradar360.com/article/499bcea5e2f44a14PharmaRadar360en2026-04-20T00:00:00.000ZWhat does the future hold for the thawing Arctic?https://www.pharmaradar360.com/article/bd0e3673b02dd417PharmaRadar360en2026-04-20T00:00:00.000ZA step-by-step guide to nailing your tenure promotion package